Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
48 participants
Mar 27, 2024
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.
Eligibility
Inclusion Criteria4
- Fully understand the study and voluntarily sign the informed consent form.
- Female 18-70 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- Life expectancy ≥ 3 months.
Exclusion Criteria1
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Interventions
ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
IV infusion
IV infusion
IV infusion
IV infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06241235